Back to Agenda
Signal Detection: Challenges and Strategic Aspects
Session Chair(s)
Alan Hochberg
Principal Scientific Enablement Director, Scientific Enablement and Processes
Genentech, A Member of the Roche Group, United States
This forum will consider three aspects of signal detection which are not frequently emphasized, but which have a significant influence on the overall quality of pharmacovigilance for a product — the role of proper identification and assessment of premarketing signals in maintaining a favorable benefit-risk profile throughout a product's life cycle, the optimization of practices and systems in ambulatory and institutional settings for reporting and tracking drug-related adverse events, and the consequences for patient benefit-risk optimization of the analysis and publication of pharmacovigilance data and safety signals by a broad array of stakeholders including academic institutions, insurers, nonprofits, and web businesses, in addition to industry and regulators.
Learning Objective : Identify opportunities, limitations, and challenges of premarketing signal detection; Describe best practices for product-specific safety monitoring in ambulatory and institutional settings; Recognize various pharmacovigilance stakeholders, their motivations, and their individual advantages and disadvantages as providers of drug safety information.
Speaker(s)
Premarketing Signaling: The What's, Why's and How's
Michael J. Klepper, MD
Drug Safety Navigator, United States
President and Founder
Optimizing Product Specific Safety Monitoring
Stella Stergiopoulos, MPH, MS
EQRx, United States
Director, Health Economic and Outcomes Research
Who Should Do Safety Signal Detection and Why (or Why Not)?
Alan Hochberg
Genentech, A Member of the Roche Group, United States
Principal Scientific Enablement Director, Scientific Enablement and Processes
Have an account?